Evidence map›Paper›PMID 36555823›Full record

ReviewInternational journal of molecular sciences2022

Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.

Cecilia Zavala-Tecuapetla, Hiram Luna-Munguia, María-Leonor López-Meraz, Manola Cuellar-Herrera

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. ExploringMedicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Cecilia Zavala-TecuapetlaLaboratory of Physiology of Reticular Formation, National Institute of Neurology and Neurosurgery, Insurgentes Sur 3877, La Fama, Mexico City 14269, Mexico.ORCID 0000-0003-0175-1511
Hiram Luna-MunguiaDepartamento de Neurobiologia Conductual y Cognitiva, Instituto de Neurobiologia, Universidad Nacional Autonoma de Mexico, Campus UNAM-Juriquilla, Queretaro 76230, Mexico.
María-Leonor López-MerazInstituto de Investigaciones Cerebrales, Universidad Veracruzana, Luis Castelazo Ayala s/n, Col. Industrial Ánimas, Xalapa 91190, Mexico.ORCID 0000-0003-0179-989X
Manola Cuellar-HerreraEpilepsy Clinic, Hospital General de México Dr. Eduardo Liceaga, Dr. Balmis 148, Doctores, Mexico City 06720, Mexico.ORCID 0000-0003-3942-2211
Hospital General de México · MXInstituto Nacional de Neurología y Neurocirugía · MXUniversidad Nacional Autónoma de México · MXUniversidad Veracruzana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of Cannabis for medicinal purposes has been documented since ancient times, where one of its principal cannabinoids extracted from

Indexed as

CannabidiolCannabinoidsCannabisEpilepsyAnticonvulsantsHumansAnticonvulsantsCannabidiolCannabinoidscannabidioldrug resistant epilepsyepilepsyphytocannabinoidspreclinical modelsseizure

Identifiers

PMID36555823
PMCPMC9783044
OpenAlexW4312194702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.